GENETIC ANALYSIS NK -60 Capital Reinvestment Ratio

Latest as of December 2025: 0.17x

GENETIC ANALYSIS NK -60 capital reinvestment ratio. GENETIC ANALYSIS NK -60 (8V8) has a Capital Reinvestment Ratio of 0.17x as of December 2025, meaning it reinvests 0% of its operating cash flow (€8.04 Million) in capital expenditures (€1.36 Million). Check GENETIC ANALYSIS NK -60 (8V8) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

0.17x

Capex / Operating Cash Flow

Operating Cash Flow

€8.04 Million

EUR

Capital Expenditures

€1.36 Million

EUR

Data as of

Dec 2025

Most recent filing

Capital Reinvestment Ratio of GENETIC ANALYSIS NK -60 (2025–2025)

Capital reinvestment ratio of GENETIC ANALYSIS NK -60 from 2025 to 2025. This chart tracks GENETIC ANALYSIS NK -60's Capital Reinvestment Ratio across 1 annual periods. Also explore 8V8 year-over-year net asset growth to track the company's year-over-year net asset growth rate.

GENETIC ANALYSIS NK -60 Capital Reinvestment Ratio by Year (2025–2025)

GENETIC ANALYSIS NK -60 capital reinvestment ratio by year from 2025 to 2025. For the full cash flow conversion analysis, see GENETIC ANALYSIS NK -60 (8V8) cash conversion ratio.

Year	Reinvestment Ratio	Operating CF (EUR)	Capital Expenditures	YoY Change
2025	2.31x	€2.40 Million	€5.54 Million	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow